CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
BI 1015550drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05633862
NCT05633862Phase 1Completed
CompareCT.gov

Pharmacokinetics, Safety and Tolerability of Doses of BI 1015550 in Healthy Chinese Male and Female Subjects (Open-label, Parallel Group Design)

Boehringer Ingelheim·interventional·Posted Dec 1, 2022·Updated Nov 28, 2025

In Brief

A Phase 1 clinical trial evaluating BI 1015550 for Healthy. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedDec 1, 2022
Enrollment StartJan 13, 2023
Primary CompletionMar 16, 2023
Study CompletionMar 17, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.6 years ago

Interventions

BI 1015550drug

A single film-coated tablet BI 1015550 taken orally after an overnight fast of at least 10 hours.